摘要
本文中,我们强调了文献报道结果,旨在阐明P2X受体的正位拮抗剂和激动剂的结构和生物活性。事实上,只有少数P2X受体激动剂已被发现,其中大部分是通过修饰天然配体ATP而得到的,他们是P2X受体没有选择性的亚型。特别是, BzATP (9)是最有效的P2X受体激动剂之一,其某些亚型的EC 50值在纳摩尔范围内。不同于激动剂, P2X受体拮抗剂属于不同的化学类别,如高分子量的聚磺酸芳分子如苏拉明及其简化衍生物和蒽醌化合物。所有这些分子被证明在P2X受体上是无选择性的,由于几个带电基团的存在它们被赋予了微摩尔活性和不利的药物动力学性质。此外修饰天然配体的ATP变形导致P2X受体拮抗剂如TNP -ATP的发现(29) ,这虽然不是选择性的,仍在P2X1 , P2X3 (IC 50分别为0.006 μM和0.001 μM)和异P2X2 / 3受体中表现出较高的效价。此外,二核苷酸肌苷磷酸盐Ip5I(33)被发现是一种有效的和选择性的P2X1和 P2X3受体的拮抗剂,其IC 50 = 0.003 μM 。过去几年,制药公司在利益的驱动下,通过使用高通量筛选,获得了有效的和赋有新颖的结构的选择性拮抗剂,其中几个目前处于一些治疗应用的临床试验阶段。
关键词: P2X1 , P2X2 , P2X3 , P2X4 , P2X5 , P2X6 , P2X7 , P2X受体激动剂, P2X受体拮抗剂。
Current Medicinal Chemistry
Title:Medicinal Chemistry of P2X Receptors: Agonists and Orthosteric Antagonists
Volume: 22 Issue: 7
Author(s): Catia Lambertucci, Diego Dal Ben, Michela Buccioni, Gabriella Marucci, Ajiroghene Thomas and Rosaria Volpini
Affiliation:
关键词: P2X1 , P2X2 , P2X3 , P2X4 , P2X5 , P2X6 , P2X7 , P2X受体激动剂, P2X受体拮抗剂。
摘要: In this work, we have highlighted data reported in the literature trying to draw a complete picture of the structures and biological activity of agonists and orthosteric antagonists of P2X receptors. Actually, only few P2X receptor agonists have been found and most of them are derived from modification of the natural ligand ATP and they are P2X receptor subtype unselective. In particular, BzATP (9) is one of the most potent P2X receptor agonists with EC50 value in the nanomolar range at some subtypes. Differently from agonists, P2X receptor antagonists belong to different chemical classes such as high molecular weight aryl polysulfonate molecules like suramin and its simplified derivatives and anthraquinone compounds. All these molecules proved to be non selective at P2X receptors, and they are endowed with micromolar activity and not favourable pharmacokinetic properties due to the presence of several charged groups. Also modification of the natural ligand ATP led to the discovery of P2X receptor antagonists like TNP-ATP (29), which, although not selective, showed high potency at P2X1, P2X3 (IC50 of 0.006 µM and 0.001 µM, respectively), and heteromeric P2X2/3 receptors. Also the dinucleotide inosine polyphosphate Ip5I (33) was found to be a potent and selective antagonist at P2X1 vs P2X3 receptors with IC50 = 0.003 µM. A significant improvement has been gained from the interest of pharmaceutical companies that in the last years discovered, through the use of high-throughput screening, potent and selective antagonists endowed with novel structures, some of which are currently in clinical trials for several therapeutic applications.
Export Options
About this article
Cite this article as:
Catia Lambertucci, Diego Dal Ben, Michela Buccioni, Gabriella Marucci, Ajiroghene Thomas and Rosaria Volpini , Medicinal Chemistry of P2X Receptors: Agonists and Orthosteric Antagonists, Current Medicinal Chemistry 2015; 22 (7) . https://dx.doi.org/10.2174/0929867321666141215093513
DOI https://dx.doi.org/10.2174/0929867321666141215093513 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Heart Transplantation in Biventricular Congenital Heart Disease: Indications, Techniques, and Outcomes
Current Cardiology Reviews Influenza and Stroke Risk: A Key Target Not to be Missed?
Infectious Disorders - Drug Targets An Efficient Synthesis of 4-Aryl-1,4-dihydropyridines Via VB1 Catalyzed Hantzsch Reaction
Letters in Organic Chemistry Covid-19 Susceptibility and Severity Might be Modified by Vitamin D Status: Theoretical and Practical Considerations
Current Respiratory Medicine Reviews Modulation of Cardiovascular Remodeling with Statins: Fact or Fiction?
Current Vascular Pharmacology Polyphenols: Biological Activities, Molecular Targets, and the Effect of Methylation
Current Molecular Pharmacology Repositioning the Old Fungicide Ciclopirox for New Medical Uses
Current Pharmaceutical Design Endothelial Dysfunction: Methods of Assessment & Implications for Cardiovascular Diseases
Current Pharmaceutical Design New Insights into the Surgical Management of Tetralogy of Fallot: Physiological Fundamentals and Clinical Relevance
Current Pediatric Reviews Vasopressin in Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Diabetes, the Renin-Angiotensin System and Heart Disease
Current Vascular Pharmacology Application of Hematopoietic Cells to Therapeutic Angiogenesis
Current Pharmaceutical Design Capsaicin Sensitive-Sensory Nerves and Blood Pressure Regulation
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Erythropoietin: New Horizon in Cardiovascular Medicine
Recent Patents on Cardiovascular Drug Discovery Novel and Emerging Drugs for Rarer Chronic Lymphoid Leukaemias
Current Cancer Drug Targets Pharmacologic Therapy for Cardiovascular Risk Reduction in Patients with the Metabolic Syndrome
Current Pharmaceutical Design Extrasynaptic GABA<sub>A</sub> Receptors in the Brainstem and Spinal Cord: Structure and Function
Current Pharmaceutical Design Cell Cycle and Cancer: The G1 Restriction Point and the G1 / S Transition
Current Genomics Quantitative Imaging Biomarkers and their Emerging Role
Current Medical Imaging Molecular Imaging of Apoptosis In Vivo with Scintigraphic and Optical Biomarkers – A Status Report
Anti-Cancer Agents in Medicinal Chemistry